Monopar Therapeutics (NASDAQ:MNPR) Trading 6.8% Higher – Should You Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price traded up 6.8% on Wednesday . The company traded as high as $105.50 and last traded at $106.5640. Approximately 132,506 shares changed hands during trading, a decline of 37% from the average session volume of 210,256 shares. The stock had previously closed at $99.79.

Analysts Set New Price Targets

A number of brokerages have recently commented on MNPR. Zacks Research upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday. BTIG Research boosted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Chardan Capital reissued a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday, March 30th. Finally, HC Wainwright restated a “buy” rating and set a $105.00 price objective on shares of Monopar Therapeutics in a report on Monday, June 29th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $108.75.

Monopar Therapeutics Stock Performance

The firm has a market capitalization of $727.08 million, a P/E ratio of -57.12 and a beta of 1.46. The stock has a 50 day moving average of $74.77 and a two-hundred day moving average of $64.80.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. Sell-side analysts predict that Monopar Therapeutics Inc. will post -2.82 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its position in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares during the period. ADAR1 Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Monopar Therapeutics in the first quarter valued at about $250,000. Siren L.L.C. grew its stake in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares during the last quarter. Finally, Sei Investments Co. grew its stake in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares during the last quarter. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.